DK2172208T3 - Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser - Google Patents

Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser

Info

Publication number
DK2172208T3
DK2172208T3 DK09015653.0T DK09015653T DK2172208T3 DK 2172208 T3 DK2172208 T3 DK 2172208T3 DK 09015653 T DK09015653 T DK 09015653T DK 2172208 T3 DK2172208 T3 DK 2172208T3
Authority
DK
Denmark
Prior art keywords
alzheimer
beta
disease
treatment
amyloid protein
Prior art date
Application number
DK09015653.0T
Other languages
English (en)
Inventor
Gerardo M Castillo
Thomas P Lake
Beth P Nguyen
Virginia J Sanders
Alan D Snow
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Application granted granted Critical
Publication of DK2172208T3 publication Critical patent/DK2172208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK09015653.0T 2003-12-18 2004-12-17 Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser DK2172208T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53140603P 2003-12-18 2003-12-18
US55434204P 2004-03-17 2004-03-17
US61561404P 2004-09-30 2004-09-30
US11/016,706 US7384910B2 (en) 1997-10-08 2004-12-16 Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
EP04814775A EP1699418A2 (en) 2003-12-18 2004-12-17 Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders

Publications (1)

Publication Number Publication Date
DK2172208T3 true DK2172208T3 (da) 2013-10-28

Family

ID=34714497

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11161614.0T DK2380583T3 (da) 2003-12-18 2004-12-17 Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DK09015653.0T DK2172208T3 (da) 2003-12-18 2004-12-17 Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11161614.0T DK2380583T3 (da) 2003-12-18 2004-12-17 Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser

Country Status (8)

Country Link
US (2) US7384910B2 (da)
EP (3) EP1699418A2 (da)
JP (2) JP4694506B2 (da)
CA (2) CA2800228C (da)
DK (2) DK2380583T3 (da)
ES (2) ES2437134T3 (da)
PT (2) PT2380583E (da)
WO (1) WO2005060683A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2732614A1 (en) * 2008-08-01 2010-02-04 Natraceutical, S.A. Obtaining cocoa extracts rich in bioactive peptides with ace and pep enzyme inhibitory activity
FR2940292B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Peptides derives d'hmg-coa reductase et composition cosmetique et/ou pharmaceutique les contenant
FR2940126B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
EP2632897B1 (en) 2010-10-29 2014-10-01 Merz Pharma GmbH & Co. KGaA Indole derivatives and process for their preparation
EP2760463B1 (en) * 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
CN102516359B (zh) * 2011-12-08 2014-05-07 重庆大学 一种抗老年痴呆症先导化合物
US20140161786A1 (en) * 2012-09-04 2014-06-12 Jonathan B. Rothbard Therapeutic compositions and related methods
JP6660877B2 (ja) 2013-09-26 2020-03-11 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用
JP6455983B2 (ja) * 2013-10-25 2019-01-23 国立大学法人神戸大学 アミロイド分解能を有する人工ペプチドおよびその利用
EP2927687A1 (en) * 2014-03-31 2015-10-07 Ecole Polytechnique Federale de Lausanne (EPFL) Agents useful in diagnostic and therapy of beta-amyloid aggregation related disorders and screening methods
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
RU2017115994A (ru) 2014-10-08 2018-11-12 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Улучшенные пептидные ингибиторы натриевых каналов
DE102015003503A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
EP3294312B1 (en) * 2015-05-12 2020-07-08 Northwestern University Materials for tissue regeneration
WO2017095250A1 (en) 2015-11-30 2017-06-08 Centro De Neurociências E Biologia Celular Peptide inhibitors of bace1 for the treatment of neurological disorders
EP3409130B1 (en) 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
KR102234027B1 (ko) * 2018-05-09 2021-03-31 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933280B2 (en) * 1996-10-08 2005-08-23 Gerardo Castillo Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
CA2268029C (en) 1996-10-08 2008-11-25 University Of Washington Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments

Also Published As

Publication number Publication date
US7384910B2 (en) 2008-06-10
US20080227721A1 (en) 2008-09-18
DK2380583T3 (da) 2013-12-02
EP2380583A1 (en) 2011-10-26
JP5221633B2 (ja) 2013-06-26
EP1699418A2 (en) 2006-09-13
CA2550085C (en) 2013-03-12
US7759311B2 (en) 2010-07-20
EP2172208B1 (en) 2013-08-07
JP4694506B2 (ja) 2011-06-08
JP2011093916A (ja) 2011-05-12
EP2380583B1 (en) 2013-08-28
PT2172208E (pt) 2013-11-11
CA2550085A1 (en) 2005-07-07
EP2172208A1 (en) 2010-04-07
US20050244334A1 (en) 2005-11-03
ES2434242T3 (es) 2013-12-16
ES2437134T3 (es) 2014-01-09
WO2005060683A2 (en) 2005-07-07
CA2800228A1 (en) 2005-07-07
JP2007535494A (ja) 2007-12-06
PT2380583E (pt) 2013-11-29
WO2005060683A3 (en) 2007-04-12
CA2800228C (en) 2015-03-24

Similar Documents

Publication Publication Date Title
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
DK2075007T3 (da) Behandling af Alzheimers sygdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
IS8004A (is) Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn
AU2003273213A8 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
DE60223674D1 (de) Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten
DE50211298D1 (de) N-(indolcarbonyl-)piperazinderivaten zur behandlung von fettsucht